sorafenib has been researched along with Lymphoma, Mantle-Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Navarro, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S | 1 |
1 other study(ies) available for sorafenib and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclin D1; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins c-bcl-2; Receptors, Antigen, B-Cell; Signal Transduction; Sorafenib; Stromal Cells; Transplantation, Heterologous | 2013 |